Innovation | Globalization I Focus

Zensun has been focused on R&D of original innovative medicine since founded and has built a product portfolio including novel therapeutics with new drug targets, new mechanisms, and new indications, including Neucardin® (rh-Neuregulin-1, recombinant human Neuregulin-1), ZS-06, and ZS-07. Among which Neucardin® is a “First-in-Class” innovative biologic under R & D via the MoA of improvement of myocardial cell structure and cardiac function, for treatment of heart failure.

View Pipeline

Zensun (Shanghai) Sci & Tech Co., Ltd. is a biopharmaceutical company focusing on the development of innovative “First-in-Class” bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. We discover new medicines using novel disease specific targets and innovative technologies. The patented discoveries are then developed into therapies. With adherence to the tenet of “Healing-for-Life”, we hope to transform the lives of heart failure patients by providing them with drugs that treat their disease and not the symptoms.

Curiosity about science and deep understanding of mechanism

Zensun’s current pipeline focuses on two basic research areas: cell signaling and energy metabolism.

New products in development include:

  • the first-in-class drug Neucardin®,gene therapy construct rAAV9.cMLCK
  • other modified drugs treating a variety of medical indications.;
  • New medical devices are also in development.

As a bio-technology company with global reach, Zensun has gathered experts and pioneers in medical research from throughout the world, and has attracted investors of forward vision and broad outlook. Zensun leverages the leading technology to best serve our patients and deliver maximum return for investors.

After more than ten years of development, Zensun is the world leader in this related field.